Effects and safety of an oral adsorbent on chronic kidney disease progression: A systematic review and meta-analysis

Ying Chun Chen, Mei Yi Wu, Ping Jen Hu, Tzu Ting Chen, Wan Chen Shen, Wei Chiao Chang, Mai Szu Wu

研究成果: 雜誌貢獻文章同行評審

14 引文 斯高帕斯(Scopus)

摘要

Background: AST-120 (Kremezin), which is an oral spherical carbon adsorbent, has been reported to have the potential for retarding disease progression in patients with chronic kidney disease. We aimed to evaluate its efficacy and safety in this study. Methods: We systematically searched for randomized controlled trials published in PubMed, Embase, and Cochrane databases. The primary outcomes were the renal outcome and all-cause mortality, and the change in serum indoxyl sulfate (IS) levels. The safety outcome was also evaluated in terms of reported major adverse events. A random-effects model was used when heterogeneity was expected. Results: Eight studies providing data for 3349 patients were included in the meta-analysis. The risk ratio of renal outcome and all-cause mortality were 0.97 (95% CI: 0.88–1.07; 6 trials) and 0.94 (0.73–1.20; 5 trials), respectively. Furthermore, the weighted mean change in IS levels from baseline to the end of the study was −0.28 mg/dL (95% CI: −0.46 to −0.11; 4 trials). Conclusions: This study provides evidence that AST-120 can effectively lower IS levels but still controversial in terms of slowing disease progression and all-cause mortality. Except for dermatological events, the incidence of adverse events did not differ significantly between the AST-120 and placebo groups.

原文英語
文章編號1718
期刊Journal of Clinical Medicine
8
發行號10
DOIs
出版狀態已發佈 - 10月 2019

ASJC Scopus subject areas

  • 醫藥 (全部)

指紋

深入研究「Effects and safety of an oral adsorbent on chronic kidney disease progression: A systematic review and meta-analysis」主題。共同形成了獨特的指紋。

引用此